Selective Inhibition of Nuclear Export (SINE) and Canine Osteosarcoma
This study is currently on hold due to the shortage of carboplatin
Osteosarcoma is a common cancer diagnosed in dogs, particularly in large breed dogs. While several chemotherapy protocols have been shown to provide modest management of the onset of metastasis (spread of cancer), we are continuously looking for additional treatments that may extend survival time.
Carboplatin is a widely accepted chemotherapy agent used in treatment of osteosarcoma. The results of this study will allow us to determine if dogs can successfully tolerate carboplatin and a new drug called Laverdia-CA1 (verdinexor) in a combination protocol.
Eligibility: Dogs seen by the Cornell University Hospital for Animals who have had limb amputation, been diagnosed with osteosarcoma, and have NOT received any chemotherapy
Compensation: This study is sponsored by the Cornell Richard P. Riney Canine Health Center. Laverdia-CA1 (verdinexor) will be provided free of charge. The sponsor will cover some of the costs you incur during carboplatin treatment. This will include $150 at each carboplatin visit (up to $600 total) and $25 at each bloodwork visit (up to $100 total). You will receive a 10% discount on your bill. You are responsible for all additional costs. Any tests or procedures unrelated to the study are your responsibility.
Owner Responsibilities: This is a 12 week study. You are responsible for administering study medications as directed and must return your dog to CUHA for follow-up appointments according to a specific timeline. All study procedures, time requirements, and responsibilities will be provided to you in a project outline.
Principal Investigator: Kelly Hume, DVM, DACVIM